Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

Table 5 Neoadjuvant treatment adverse effects

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	χ2	P value
WHO grading
0	7 (25%)	16 (26.23%)	0.015	0.902
I	8 (28.57%)	21 (34.43%)	0.299	0.584
II	9 (32.14%)	15 (24.59%)	0.566	0.456
III	4 (14.29%)	9 (14.75%)	0.003	0.954
IV	0	0
WBC decreased			0.023	0.881
Grade 0, 1	24 (85.71%)	53 (86.88%)
Grade 2, 3, 4	4 (14.29%)	8 (13.11%)
HGB decreased			0.026	0.873
Grade 0, 1	22 (78.57%)	47 (77.05%)
Grade 2, 3, 4	6 (21.43%)	14 (22.95%)
Platelet count decreased			2.324	0.127
Grade 0, 1	24 (85.71%)	58 (95.08%)
Grade 2, 3, 4	4 (14.29%)	3 (4.92%)
Neutrophil count decreased			0.140	0.708
Grade 0, 1	24 (85.71%)	54 (88.52%)
Grade 2, 3, 4	4 (14.29%)	7 (11.48%)
Other adverse effects			0.458	0.499
Grade 0, 1	25 (89.29%)	59 (96.72%)
Grade 2, 3, 4	3 (10.71%)	2 (3.28%)

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; WBC: White blood count; HGB: Hemoglobin.